Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 480

1.

Maximum renal responses to renin inhibition in healthy study participants: VTP-27999 versus aliskiren.

Barkoudah E, van Thiel BS, Fisher ND, Gregg RA, Danser AH, Moukarbel GV, Hollenberg NK.

J Hypertens. 2016 May;34(5):935-41. doi: 10.1097/HJH.0000000000000860.

PMID:
26882043
2.

Habitual flavonoid intake and endothelial function in healthy humans.

Fisher ND, Hurwitz S, Hollenberg NK.

J Am Coll Nutr. 2012 Aug;31(4):275-9.

3.

Is there room for dual blockade of the renin-angiotensin-aldosterone system?

Hollenberg NK.

J Hypertens. 2012 Apr;30(4):671-2. doi: 10.1097/HJH.0b013e328350149d. No abstract available.

PMID:
22418900
4.

Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study.

Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH.

J Renin Angiotensin Aldosterone Syst. 2012 Jun;13(2):250-3. doi: 10.1177/1470320312437068. Epub 2012 Feb 16.

PMID:
22345094
5.

Flavonoids [corrected] and blood pressure.

Hollenberg NK.

Am J Clin Nutr. 2012 Feb;95(2):271. doi: 10.3945/ajcn.111.031112. Epub 2011 Dec 28. No abstract available. Erratum in: Am J Clin Nutr. 2012 May;95(5):1297.

PMID:
22205308
6.

Correlation of cystatin-C with glomerular filtration rate by inulin clearance in pregnancy.

Saxena AR, Ananth Karumanchi S, Fan SL, Horowitz GL, Hollenberg NK, Graves SW, Seely EW.

Hypertens Pregnancy. 2012;31(1):22-30. doi: 10.3109/10641955.2010.507845. Epub 2011 Oct 18.

7.

Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients?

Hollenberg NK, Fisher ND, Nussberger J, Moukarbel GV, Barkoudah E, Danser AH.

J Hypertens. 2011 Dec;29(12):2454-61. doi: 10.1097/HJH.0b013e32834c627a.

8.

Evaluation of a direct prorenin assay making use of a monoclonal antibody directed against residues 32-39 of the prosegment.

Krop M, van Gool JM, Day D, Hollenberg NK, Jan Danser AH.

J Hypertens. 2011 Nov;29(11):2138-46. doi: 10.1097/HJH.0b013e32834b1978.

PMID:
21881521
9.

Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients.

Weir MR, Hollenberg NK, Remuzzi G, Zappe DH, Meng X, Parving HH.

J Hypertens. 2011 Oct;29(10):2031-7. doi: 10.1097/HJH.0b013e32834a8a25.

PMID:
21841500
10.

Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy.

Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Hans-Henrik P.

J Renin Angiotensin Aldosterone Syst. 2012 Mar;13(1):118-21. doi: 10.1177/1470320311417272. Epub 2011 Aug 8.

PMID:
21824990
11.

Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy.

Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH.

Clin J Am Soc Nephrol. 2011 May;6(5):1025-31. doi: 10.2215/CJN.07590810. Epub 2011 Feb 24.

12.

Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy.

Persson F, Lewis JB, Lewis EJ, Rossing P, Hollenberg NK, Parving HH; AVOID Study Investigators.

Diabetes Care. 2010 Nov;33(11):2304-9. doi: 10.2337/dc10-0833. Epub 2010 Aug 6.

13.

Brain blood flow and velocity: correlations between magnetic resonance imaging and transcranial Doppler sonography.

Sorond FA, Hollenberg NK, Panych LP, Fisher ND.

J Ultrasound Med. 2010 Jul;29(7):1017-22.

14.

Renal plasma flow: glomerular filtration rate relationships in man during direct renin inhibition with aliskiren.

Splenser AE, Fisher ND, Danser AH, Hollenberg NK.

J Am Soc Hypertens. 2009 Sep-Oct;3(5):315-20. doi: 10.1016/j.jash.2009.06.004. Epub 2009 Aug 19.

PMID:
20409974
15.

Flavanols, the Kuna, cocoa consumption, and nitric oxide.

Hollenberg NK, Fisher ND, McCullough ML.

J Am Soc Hypertens. 2009 Mar-Apr;3(2):105-12. doi: 10.1016/j.jash.2008.11.001. Epub 2009 Feb 20.

16.

Direct renin inhibition and the kidney.

Hollenberg NK.

Nat Rev Nephrol. 2010 Jan;6(1):49-55. doi: 10.1038/nrneph.2009.201. Epub 2009 Nov 24. Review.

PMID:
19935744
17.

Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria.

Weir MR, Hollenberg NK, Zappe DH, Meng X, Parving HH, Viberti G, Remuzzi G.

J Hypertens. 2010 Jan;28(1):186-93. doi: 10.1097/HJH.0b013e328332bd61.

PMID:
19809363
18.

A comparison of prediction equations for estimating glomerular filtration rate in pregnancy.

Ahmed SB, Bentley-Lewis R, Hollenberg NK, Graves SW, Seely EW.

Hypertens Pregnancy. 2009;28(3):243-55. doi: 10.1080/10641950801986720.

19.

[Aliskiren combined with losartan in type 2-diabetes and nephropathy - secondary publication].

Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK.

Ugeskr Laeger. 2009 Mar 9;171(11):881-4. Danish.

PMID:
19291865
20.

Cocoa and cardiovascular health.

Corti R, Flammer AJ, Hollenberg NK, L├╝scher TF.

Circulation. 2009 Mar 17;119(10):1433-41. doi: 10.1161/CIRCULATIONAHA.108.827022. Review.

21.

Oral contraceptive progestins and angiotensin-dependent control of the renal circulation in humans.

Sarna MA, Hollenberg NK, Seely EW, Ahmed SB.

J Hum Hypertens. 2009 Jun;23(6):407-14. doi: 10.1038/jhh.2008.148. Epub 2009 Jan 22.

22.

Aliskiren accumulates in Renin secretory granules and binds plasma prorenin.

Krop M, Garrelds IM, de Bruin RJ, van Gool JM, Fisher ND, Hollenberg NK, Jan Danser AH.

Hypertension. 2008 Dec;52(6):1076-83. doi: 10.1161/HYPERTENSIONAHA.108.123042. Epub 2008 Nov 3.

PMID:
18981317
23.

Cerebral blood flow response to flavanol-rich cocoa in healthy elderly humans.

Sorond FA, Lipsitz LA, Hollenberg NK, Fisher ND.

Neuropsychiatr Dis Treat. 2008 Apr;4(2):433-40.

24.

Influencing the natural history of hypertension: is it the blood pressure achieved, the drug, or the drug dose?

Hollenberg NK.

J Hypertens. 2008 Aug;26(8):1527-32. doi: 10.1097/HJH.0b013e328303e60b. Review. No abstract available.

PMID:
18622224
25.

Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.

Fisher ND, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK.

Circulation. 2008 Jun 24;117(25):3199-205. doi: 10.1161/CIRCULATIONAHA.108.767202. Epub 2008 Jun 16.

PMID:
18559696
26.

Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators.

N Engl J Med. 2008 Jun 5;358(23):2433-46. doi: 10.1056/NEJMoa0708379.

27.

Is it the dark in dark chocolate?

Hollenberg NK, Fisher ND.

Circulation. 2007 Nov 20;116(21):2360-2. No abstract available.

PMID:
18025400
28.

Mortality in type 2 diabetes mellitus.

Hollenberg NK.

J Hypertens. 2007 Dec;25(12):2381-2. No abstract available.

PMID:
17984657
29.

Renin inhibition: what are the clinical perspectives?

Hollenberg NK.

Semin Nephrol. 2007 Sep;27(5):511-8. Review.

PMID:
17868787
30.

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.

Hollenberg NK, Parving HH, Viberti G, Remuzzi G, Ritter S, Zelenkofske S, Kandra A, Daley WL, Rocha R.

J Hypertens. 2007 Sep;25(9):1921-6.

PMID:
17762658
31.

Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be?

Hollenberg NK, Epstein M.

Clin J Am Soc Nephrol. 2006 Sep;1(5):1046-8. Epub 2006 Jul 19. Review. No abstract available.

32.

Short- and long-term glycaemic control and the state of the renin system in type 1 diabetes mellitus.

Stevanovic RD, Fisher ND, Lansang CM, Freeman KD, Hollenberg NK.

J Renin Angiotensin Aldosterone Syst. 2007 Jun;8(2):85-92.

PMID:
17703435
33.

A brief response to Sealey and Laragh.

Hollenberg NK.

J Renin Angiotensin Aldosterone Syst. 2007 Jun;8(2):53. No abstract available.

PMID:
17703429
34.

Gender and the renal nitric oxide synthase system in healthy humans.

Ahmed SB, Fisher ND, Hollenberg NK.

Clin J Am Soc Nephrol. 2007 Sep;2(5):926-31. Epub 2007 Aug 8.

35.
37.

Insulin induces renal vasodilation, increases plasma renin activity, and sensitizes the renal vasculature to angiotensin receptor blockade in healthy subjects.

Perlstein TS, Gerhard-Herman M, Hollenberg NK, Williams GH, Thomas A.

J Am Soc Nephrol. 2007 Mar;18(3):944-51. Epub 2007 Feb 7.

38.

Obesity and the kidney: why is the kidney at risk?

Hollenberg NK.

Kidney Int. 2007 Feb;71(3):187-8.

39.

Organ systems dependent on nitric oxide and the potential for nitric oxide-targeted therapies in related diseases.

Hollenberg NK.

J Clin Hypertens (Greenwich). 2006 Dec;8(12 Suppl 4):63-73. Review.

40.

Effects of the PPAR-gamma agonist rosiglitazone on renal haemodynamics and the renin-angiotensin system in diabetes.

Lansang MC, Coletti C, Ahmed S, Gordon MS, Hollenberg NK.

J Renin Angiotensin Aldosterone Syst. 2006 Sep;7(3):175-80.

PMID:
17094055
41.

Prorenin and angiotensin-dependent renal vasoconstriction in type 1 and type 2 diabetes.

Stankovic AR, Fisher ND, Hollenberg NK.

J Am Soc Nephrol. 2006 Dec;17(12):3293-9. Epub 2006 Nov 8.

42.

Aging and vascular responses to flavanol-rich cocoa.

Fisher ND, Hollenberg NK.

J Hypertens. 2006 Aug;24(8):1575-80.

PMID:
16877960
43.

Cocoa flavanols and brain perfusion.

Fisher ND, Sorond FA, Hollenberg NK.

J Cardiovasc Pharmacol. 2006;47 Suppl 2:S210-4.

PMID:
16794460
44.

Hypertension, the Kuna, and the epidemiology of flavanols.

McCullough ML, Chevaux K, Jackson L, Preston M, Martinez G, Schmitz HH, Coletti C, Campos H, Hollenberg NK.

J Cardiovasc Pharmacol. 2006;47 Suppl 2:S103-9; discussion 119-21.

PMID:
16794446
45.

The influence of dietary sodium on blood pressure.

Hollenberg NK.

J Am Coll Nutr. 2006 Jun;25(3 Suppl):240S-246S. Review.

PMID:
16772635
46.

Nonmodulation and essential hypertension.

Hollenberg NK, Williams GH.

Curr Hypertens Rep. 2006 May;8(2):127-31. Review.

PMID:
16672145
47.

Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data.

Halpern MT, Khan ZM, Schmier JK, Burnier M, Caro JJ, Cramer J, Daley WL, Gurwitz J, Hollenberg NK.

Hypertension. 2006 Jun;47(6):1039-48. Epub 2006 May 1. Review. No abstract available.

PMID:
16651464
48.

Diabetes, nephropathy, and the renin system.

Hollenberg NK.

J Hypertens Suppl. 2006 Mar;24(1):S81-7. Review.

PMID:
16601578
49.

Renin inhibition with aliskiren: where are we now, and where are we going?

Azizi M, Webb R, Nussberger J, Hollenberg NK.

J Hypertens. 2006 Feb;24(2):243-56. Review.

PMID:
16508564
50.

Omission of drug dose information.

Hollenberg NK.

Arch Intern Med. 2006 Feb 13;166(3):368; author reply 368-9. No abstract available.

PMID:
16476880

Supplemental Content

Loading ...
Support Center